Vireo Growth (VREOF) Capital Expenditures (2020 - 2026)
Vireo Growth (VREOF) posted Capital Expenditures of $10.8 million for Q1 2026, up 9.51% sequentially from $9.9 million in Q4 2025, and up 881.82% YoY from $1.1 million in Q1 2025.
Vireo Growth (VREOF) Capital Expenditures (2020 - 2026) Analysis & Trends
Vireo Growth has reported Capital Expenditures for 7 years, with the latest figure at $10.8 million in Q1 2026.
- Quarterly Capital Expenditures rose 881.82% year-over-year to $10.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $38.0 million (up 219.65% YoY) and the FY2025 annual result came in at $28.3 million, up 142.19% from the prior year.
- Capital Expenditures improved to $10.8 million in Q1 2026 per VREOF's latest filing, from $9.9 million in the prior quarter.
- Over five years, Capital Expenditures peaked at $13.7 million in Q3 2025 and troughed at $152079.0 in Q3 2023.
- A 5-year average of $3.6 million and a median of $2.3 million in 2023 frame the typical range for Capital Expenditures.
- The sharpest annual moves came in 2023 and 2024: Capital Expenditures plunged 90.9% in 2023, then surged 3112.91% in 2024.
- Over 5 years, Capital Expenditures stood at $623076.0 in 2022, then jumped by 274.33% to $2.3 million in 2023, then increased by 16.62% to $2.7 million in 2024, then surged by 262.57% to $9.9 million in 2025, then rose by 9.51% to $10.8 million in 2026.
- According to Business Quant data, Capital Expenditures over the past three periods registered $10.8 million, $9.9 million, and $13.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.42 Bn | 39.76 Bn | 2.15 Bn | 104.00 Mn |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | 117.00 Mn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.98 Bn | 5.10 Bn | -337.60 Mn |
| 5 | United Therapeutics | 22.29 Bn | 19.63 Bn | 683.80 Mn | 108.00 Mn |
| 6 | Viatris | 18.78 Bn | 17.89 Bn | 1.46 Bn | 52.80 Mn |
| 7 | Neurocrine Biosciences | 15.66 Bn | 15.27 Bn | 935.80 Mn | 7.80 Mn |
| 8 | Elanco Animal Health | 11.91 Bn | 11.38 Bn | 798.00 Mn | 33.00 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | - |
| 10 | Vireo Growth | 491.44 Mn | 349.14 Mn | 95.30 Mn | 108.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.80 Mn |
| Mar 31, 2026 | 10.80 Mn |
| Dec 31, 2025 | 9.86 Mn |
| Dec 31, 2025 | 9.86 Mn |
| Sep 30, 2025 | 13.66 Mn |
| Sep 30, 2025 | 13.66 Mn |
| Jun 30, 2025 | 3.70 Mn |
| Jun 30, 2025 | 3.70 Mn |
| Mar 31, 2025 | 1.10 Mn |
| Mar 31, 2025 | 1.10 Mn |
| Dec 31, 2024 | 2.72 Mn |
| Dec 31, 2024 | 2.72 Mn |
| Sep 30, 2024 | 4.89 Mn |
| Sep 30, 2024 | 4.89 Mn |
| Jun 30, 2024 | 3.19 Mn |
| Jun 30, 2024 | 3.19 Mn |
| Mar 31, 2024 | 899,264.00 |
| Mar 31, 2024 | 899,264.00 |
| Dec 31, 2023 | 2.33 Mn |
| Dec 31, 2023 | 2.33 Mn |